Literature DB >> 8068612

Inhibition of hepatic ACAT decreases ApoB secretion in miniature pigs fed a cholesterol-free diet.

M W Huff1, D E Telford, P H Barrett, J T Billheimer, P J Gillies.   

Abstract

To test the hypothesis that hepatic cholesteryl ester is involved in the regulation of apolipoprotein (apo) B secretion into plasma, apoB kinetic studies were performed in six control miniature pigs and in six pigs after a 21-day administration of the acyl coenzyme A:cholesterol acyltransferase (ACAT) inhibitor DuP 128 (2.2 mg.kg-1.d-1 i.v.). Pigs were fed low-fat, cholesterol-free diets. Total plasma cholesterol, triglyceride, very-low-density lipoprotein (VLDL) triglyceride, and low-density lipoprotein (LDL) cholesterol decreased 18%, 29%, 40%, and 26% respectively (P < .03). 131I-VLDL and 125I-LDL were injected simultaneously into each animal, and apoB kinetics were analyzed by using multi-compartmental analysis (SAAM30). VLDL apoB pool size decreased significantly by 60% (0.32 versus 0.84 mg/kg), which was due to a 65% reduction in the VLDL apoB production or secretion rate (1.03 versus 2.94 mg.kg-1.h-1). The fractional catabolic rate was unchanged. LDL apoB pool size decreased nonsignificantly by 18% (5.61 versus 6.90 mg/kg) due entirely to a 24% decrease in production rate (0.26 versus 0.34 mg.kg-1.h-1). At necropsy, hepatic microsomal ACAT activity decreased by 68% (0.28 versus 0.88 nmol.min-1.mg-1; P < .0002). Although an increase in hepatic free cholesterol leading to a decreased LDL receptor expression might be expected, this did not occur. The concentration of hepatic cholesterol and the LDL apoB fractional catabolic rate were unaffected by DuP 128. In addition, the concentration of hepatic triglyceride and the activity of diacylglycerol acyltransferase were not altered by DuP 128, indicating a lack of effect of DuP 128 on hepatic triglyceride metabolism. We conclude that inhibition of hepatic cholesteryl ester synthesis in vivo decreases apoB secretion into plasma.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8068612     DOI: 10.1161/01.atv.14.9.1498

Source DB:  PubMed          Journal:  Arterioscler Thromb        ISSN: 1049-8834


  5 in total

Review 1.  New targets for medical treatment of lipid disorders.

Authors:  Margaret E Brousseau; Ernst J Schaefer
Journal:  Curr Atheroscler Rep       Date:  2002-09       Impact factor: 5.113

2.  Pharmacokinetic properties of YM17E, an inhibitor of acyl coenzyme A: cholesterol acyl transferase, and serum cholesterol levels in healthy volunteers.

Authors:  T Uchida; T Usui; T Watanabe; S Higuchi; M Nakata; K Maezawa; Y Kikawa; M Tsunoo; N Nakaya; Y Goto
Journal:  Eur J Clin Pharmacol       Date:  1997       Impact factor: 2.953

3.  ACAT1 and ACAT2 membrane topology segregates a serine residue essential for activity to opposite sides of the endoplasmic reticulum membrane.

Authors:  C W Joyce; G S Shelness; M A Davis; R G Lee; K Skinner; R A Anderson; L L Rudel
Journal:  Mol Biol Cell       Date:  2000-11       Impact factor: 4.138

Review 4.  Inhibition of acyl coenzyme A-cholesterol acyltransferase: a possible treatment of atherosclerosis?

Authors:  Therese M Heinonen
Journal:  Curr Atheroscler Rep       Date:  2002-01       Impact factor: 5.113

5.  Apigenin Ameliorates Dyslipidemia, Hepatic Steatosis and Insulin Resistance by Modulating Metabolic and Transcriptional Profiles in the Liver of High-Fat Diet-Induced Obese Mice.

Authors:  Un Ju Jung; Yun-Young Cho; Myung-Sook Choi
Journal:  Nutrients       Date:  2016-05-19       Impact factor: 5.717

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.